Final overall survival analysis
WebMay 31, 2024 · For the final overall survival analysis, 410 deaths were required to provide approximately 80% power to detect a hazard ratio of 0.75 with a two-tailed significance level of 0.045. WebApr 19, 2015 · Final overall survival analysis will be performed after at least 435 deaths have occurred in all the study groups or when all patients have been followed for at least 21 months. All data presented ...
Final overall survival analysis
Did you know?
WebMay 16, 2024 · At the final OS analysis, duration of follow-up was comparable between arms, with a median follow-up duration for OS of 45.7 months (95% CI, 42.7 to 48.8 months) with crizotinib and 45.5 months …
WebSep 19, 2024 · A final overall survival (OS) analysis showed that the addition of tamoxifen to abemaciclib demonstrated a median OS of more than 24 months with progression-free survival (PFS) consistent to primary study results in patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast … WebFeb 1, 2024 · This approval was based on significantly improved median overall survival compared with 5-FU/LV alone (6.1 vs 4.2 months; hazard ratio [HR], 0.67) in the global phase 3 NAPOLI-1 trial. Here, we report the final survival analysis and baseline characteristics associated with long-term survivors (survival of ≥1 year) in the NAPOLI-1 …
WebMar 22, 2024 · The latest analysis of the MONALEESA-2 study showed a significant and clinically meaningful difference in OS of 12.5 months with first-line ribociclib plus letrozole as compared with placebo plus letrozole in postmenopausal patients with advanced HR-positive, HER2-negative breast cancer, with a 24% relative reduction in the risk of death. WebOverall survival (OS) is the gold standard primary end point to evaluate the outcome of any drug, biologic, intervention, or procedure that is assessed in oncologic clinical trials. OS …
WebIn the preplanned final analysis of overall survival according to the protocol, median overall survival was longer with nivolumab plus cabozantinib versus sunitinib (37·7 months vs 34·3 months; HR 0·70 [95% CI 0·55−0·90]). Median progression-free survival was twice as long with nivolumab plus cabozantinib than sunitinib.
WebAug 1, 2024 · However, OS at this final analysis was not fully powered because the number of events was 83, which is approximately half of the planned number of 150 events. The final OS analysis was planned to be conducted when 150 events had accrued or when the sponsor decided to terminate the trial, whichever occurred first. ... Updated overall … the abbey shrewsburyWebThe final analysis of overall survival was prespecified to occur either after 158 deaths had occurred or 5 years after the last patient was randomised, whichever occurred first. Safety was also a secondary endpoint. The … the abbey songWebIn the ITT population, the event rates were 54.8% for the atezolizumab plus bevacizumab group and 55.3% for the sunitinib group, and the overall survivals were 36.1 months (95% CI, 31.5-42.3 months) for the … the abbey sonterraWebMar 1, 2024 · We report final efficacy and safety outcomes after an additional 15.6 months of overall survival (OS) follow-up in patients from the HER2CLIMB trial. HER2CLIMB met statistical significance for all primary and alpha-controlled secondary endpoints at the primary analysis; therefore, this follow-up analysis is descriptive only. the abbey shrewsbury menuWebApr 12, 2024 · The protocol-specified final analysis of overall survival was to be done 12 months after the second interim analysis, which would allow the comparison of superiority of pembrolizumab versus chemotherapy to have 85% power to show a hazard ratio (HR) of 0·62 for overall survival at the one-sided α level of 1·25%, with a planned sample size … the abbey shrewsbury christmas menuWebFeb 16, 2024 · Final overall survival analysis and organ-specific target lesion assessments with two-year follow-up in CheckMate 9ER: Nivolumab plus cabozantinib … the abbey shrewsbury pubWebMay 28, 2024 · Here, we present the final overall survival (OS) results from the study. Methods: This was a multicenter (17 centers in China) phase II randomized controlled trial of erlotinib（E）versus gemcitabine plus cisplatin (GC) as neoadjuvant/adjuvant therapy in pts with stage IIIA-N2 NSCLC with EGFR mutations in exon 19 or 21. From Dec 2011 to Dec ... the abbey springfield mo